Peptides for Erectile Dysfunction: PT-141 and Other Options

Key Takeaways

• Compounds discussed: PT-141 (bremelanotide), kisspeptin, gonadorelin — each with distinct regulatory status and different evidence bases, none FDA-approved for erectile dysfunction in men
• Goal area: Contextual education about peptides discussed in sexual health research; not a treatment guide for ED
• Evidence range: Ranges from early Phase II trials in men that did not result in FDA approval for a male ED indication (PT-141) to preclinical and early human data studied in different populations (kisspeptin, in men with HSDD — not ED)
• Regulatory status: PT-141 is FDA-approved as Vyleesi only for HSDD in premenopausal women; use for ED in men is off-label. Kisspeptin is not FDA-approved and is not available through 503A compounding pharmacies for therapeutic use. Gonadorelin is not FDA-approved for sexual dysfunction; previously-approved products (Factrel, Lutrepulse) have been withdrawn and compounded availability varies.
• Key biomarkers for ED: Total testosterone, free testosterone, LH, FSH, estradiol, SHBG, prolactin, fasting glucose, HbA1c, hs-CRP
• As of April 2026: PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women; its use for erectile dysfunction in men has not been approved by the FDA. Peptide bulk drug substances are undergoing significant regulatory change in 2026; consult a licensed prescriber for current availability.
• Bottom line: PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is not FDA-approved for erectile dysfunction in men. Early Phase II trials in men reported erectile response signals but were not sufficient to support an FDA ED indication. Multiple contributing causes of ED warrant biomarker evaluation before any peptide discussion with a licensed provider.

Understanding Erectile Dysfunction: The Biology

Erectile dysfunction is not a single-mechanism condition. It represents the final common expression of several distinct physiological disruptions: vascular, neurological, hormonal, and psychological. Understanding which mechanism predominates in a given individual is clinically necessary before any therapeutic discussion can be meaningful.

The conventional framework of erectile physiology begins with sexual arousal activating parasympathetic nerve signals that release nitric oxide (NO) in the penile vasculature. NO activates guanylate cyclase, producing cyclic guanosine monophosphate (cGMP), which relaxes smooth muscle in the corpus cavernosum and allows blood inflow sufficient for erection. Phosphodiesterase type 5 (PDE5) degrades cGMP, and inhibiting PDE5 (as sildenafil and tadalafil do) prolongs this vascular response. This peripheral pathway is what the most widely prescribed ED medications address.

What this framework underemphasizes is the centrally mediated component. Sexual desire, arousal signals, and the neurological coordination of erection originate in the brain — the hypothalamus, limbic system, and spinal cord — before any peripheral vascular event occurs. The melanocortin system, specifically MC3R and MC4R receptors in the hypothalamus and spinal cord, plays a documented role in this central circuitry. Martin and colleagues, in a 2002 study in the European Journal of Pharmacology, showed MC4R agonism increases erectile activity in animal models. Martin and MacIntyre, in a 2004 European Urology review, melanocortin receptor function in erectile physiology — the neuroanatomical basis for the central mechanism.

Hormonal contributions to ED represent a third distinct pathway. Testosterone does not directly cause erections, but it is required for maintaining libido, penile tissue health, and appropriate sensitivity to CNS arousal signals. When testosterone is low, the entire arousal-erection cascade is attenuated, independent of vascular function.

Peptides Discussed in Sexual Health Research: Mechanism and Evidence Summary

The following peptides appear in published research relevant to sexual health. This summary is educational; none is FDA-approved for erectile dysfunction in men.

• Compound: PT-141 (bremelanotide)
  Mechanism studied: Melanocortin MC3R/MC4R agonism in CNS — researched as a central arousal pathway distinct from the nitric oxide-cGMP pathway
  Evidence: Phase II studies in men (Diamond et al. 2004, N=68 per arm; Rosen et al. 2004 in PDE5 non-responders) reported erectile response signals but did not proceed to FDA approval for male indications; FDA's subsequent review focused on HSDD in premenopausal women, resulting in the 2019 Vyleesi approval. The safety profile in the male ED Phase II studies included blood pressure elevation and other adverse events that FDA considered in its review
  FDA status: FDA-approved as Vyleesi for HSDD in premenopausal women. Not FDA-approved for erectile dysfunction in men; use for ED in men is off-label
  SP availability: Superpower members can connect with licensed providers through the Superpower platform; Superpower does not prescribe or dispense medications. Any provider evaluation for use in men would be off-label
  Route (as approved): Vyleesi is subcutaneous injection
• Compound: Kisspeptin
  Mechanism studied: Stimulates hypothalamic GnRH release, driving LH and testosterone secretion; activates sexual brain processing in functional neuroimaging
  Evidence: Phase II RCT data in men with HSDD (Dhillo et al. 2023 in JAMA Network Open) — the study population was men with HSDD, not men with ED; Phase I human endocrine data (Dhillo et al. 2005)
  FDA status: Not FDA-approved for any indication. Kisspeptin is not on the FDA 503A bulks list and is not available through 503A compounding pharmacies for therapeutic use in the United States
  SP availability: Not offered. Kisspeptin is studied in academic research protocols only
  Route: Subcutaneous injection or intravenous (clinical research context)
• Compound: Gonadorelin
  Mechanism studied: GnRH analog that stimulates LH and FSH when administered in pulsatile pattern
  Evidence: Established endocrine pharmacology for HPG axis evaluation and pulsatile hormone replacement; no dedicated ED-specific Phase II trials
  FDA status: Previously-approved gonadorelin products (Factrel, Lutrepulse) have been withdrawn from the US market. Not FDA-approved for sexual dysfunction. Use for ED is off-label. Compounding under Section 503A depends on gonadorelin's current classification under FDA's §503A bulk drug substances evaluation, which is ongoing
  SP availability: Superpower does not facilitate access to gonadorelin for ED. Any clinical use would be in HPG axis evaluation or hypogonadotropic hypogonadism-related applications, per a licensed prescriber's evaluation
  Route: Subcutaneous injection

Peptides Discussed in Sexual Health Research: Individual Profiles

Each compound has a distinct mechanism, evidence base, and regulatory status. A clinical evaluation considers all three before any recommendation is made.

PT-141 (bremelanotide)

PT-141 (bremelanotide) is the active ingredient in Vyleesi, an FDA-approved product indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. The discussion below concerns off-label use of compounded bremelanotide in men with erectile dysfunction; this use has not been evaluated or approved by the FDA. Compounded bremelanotide is not the FDA-approved product; because Vyleesi is commercially available, 503A compounding of bremelanotide is restricted under FDA's essentially-a-copy framework.

PT-141 is a synthetic cyclic heptapeptide and melanocortin receptor agonist. Its studied mechanism operates through central melanocortin pathways rather than the peripheral nitric oxide-cGMP pathway targeted by PDE5 inhibitors. Van der Ploeg and colleagues established in a 2002 PNAS study that MC4R has a role in erectogenic CNS circuitry. Wessells and colleagues, in a 2005 Peptides study, described melanocortin-induced erection pathways independent of peripheral nitric oxide. Pfaus and colleagues, in a 2022 CNS Spectrums review, detailed the central melanocortin pathway that PT-141 engages.

Early male-ED research conducted prior to Vyleesi's FDA approval for HSDD in women included Phase II double-blind placebo-controlled studies (Diamond et al., 2004, International Journal of Impotence Research; Phase II data), subcutaneous-route studies in men with inadequate sildenafil response (Rosen et al., 2004, Phase II data), and additional Phase II work in PDE5-inhibitor non-responders (Safarinejad and Hosseini, 2008, Journal of Urology, Phase II data). These Phase II signals in men were not sufficient to support an FDA approval for male ED; FDA's subsequent review focused on HSDD in premenopausal women, resulting in the 2019 Vyleesi approval. The safety profile in the male ED Phase II studies included blood pressure elevation and other adverse events that FDA considered in its review. [Phase II signals in men; did not lead to FDA approval for ED in men]

PT-141 is FDA-approved as Vyleesi for HSDD in premenopausal women. Its use for erectile dysfunction in men has not been approved by the FDA; the safety and efficacy for this indication have not been established through adequate and well-controlled clinical trials in men under the FDA review process. Compounded bremelanotide is not the FDA-approved product Vyleesi. Because Vyleesi is commercially available, 503A compounding of bremelanotide is limited under FDA's essentially-a-copy framework (FDCA § 353a(b)(1)(D)) to patients for whom a licensed prescriber documents a specific clinical difference from the approved product. Superpower members can connect with licensed providers through the Superpower platform; Superpower does not prescribe or dispense medications. Any provider evaluation for use in men would be off-label; FDA has not approved bremelanotide for erectile dysfunction in men. Common adverse effects include nausea, flushing, and transient blood pressure elevation; individuals taking nitrates or other vasodilators, or with uncontrolled hypertension or cardiovascular disease, should not use bremelanotide without provider evaluation.

Kisspeptin

Kisspeptin is an endogenous neuropeptide produced predominantly in the arcuate and anteroventral periventricular nuclei of the hypothalamus. It is the key upstream activator of the HPG axis and also mediates direct sexual arousal pathways independent of its hormonal effects.

For sexual health research, kisspeptin has been studied across two distinct mechanisms: hormonal (stimulating endogenous testosterone via GnRH-LH signaling) and direct sexual arousal (activating limbic and mesolimbic brain regions involved in sexual motivation). Dhillo and colleagues, in a 2005 Journal of Clinical Endocrinology and Metabolism study, showed kisspeptin-54 stimulates LH and testosterone, establishing its HPG axis effect. In a 2023 randomized controlled trial published in JAMA Network Open, Dhillo and colleagues reported kisspeptin increased penile tumescence and sexual brain processing in men with hypoactive sexual desire disorder — the study population was men with HSDD, not men with erectile dysfunction, and whether the findings generalize to men with ED has not been established. [Phase II RCT in men with HSDD; Phase I for HPG axis effects]

Kisspeptin is not FDA-approved for any indication. It is not on the FDA 503A bulks list and is not a component of an FDA-approved drug; kisspeptin is not available through 503A compounding pharmacies for therapeutic use in the United States. Research on kisspeptin is limited to academic research settings. Superpower does not facilitate access to kisspeptin.

Gonadorelin

Gonadorelin is a synthetic decapeptide identical in sequence to endogenous GnRH (gonadotropin-releasing hormone). When administered in a pulsatile pattern, it stimulates pituitary LH and FSH release, which in turn drives testicular testosterone production. Previously-approved gonadorelin products (Factrel, Lutrepulse) have been withdrawn from the US market.

Gonadorelin is not studied for erectile dysfunction as a direct target. It is discussed here only in the context of secondary hypogonadism — a contributing factor for some cases of ED that may warrant endocrine evaluation with a licensed provider. [Established endocrine pharmacology; no dedicated ED-specific Phase II trials]

Gonadorelin is not FDA-approved for sexual dysfunction in men. Previously-approved US gonadorelin products (Factrel, Lutrepulse) have been withdrawn from the US market and are not currently commercially available; the essentially-a-copy analysis under FDCA § 353a(b)(1)(D) therefore does not restrict compounding of gonadorelin on commercial-availability grounds. Compounding eligibility under 503A depends on the bulk drug substance classification under FDA's §503A bulks evaluation. Superpower does not facilitate access to gonadorelin for ED. Any clinical use would be in diagnostic evaluation of HPG axis function or as prescribed by a licensed physician for specific clinical presentations of hypogonadotropic hypogonadism — not as an ED treatment.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry different regulatory statuses. These distinctions are directly relevant when discussing any of them with a healthcare provider.

• PT-141 (bremelanotide): FDA-approved as Vyleesi for HSDD in premenopausal women (2019). Not FDA-approved for erectile dysfunction in men; male use is off-label. Compounded bremelanotide is not the FDA-approved product. Because Vyleesi is commercially available, 503A compounding of bremelanotide copies is limited under FDA's essentially-a-copy framework (FDCA § 353a(b)(1)(D)) to patients for whom a prescriber documents a specific clinical difference from the approved product.
• Kisspeptin: Not FDA-approved for any indication. Kisspeptin is not on the FDA 503A bulks list, not a component of an FDA-approved drug, and not the subject of a USP/NF monograph; it is not available through 503A compounding pharmacies for therapeutic use in the United States. Research use is in academic research settings.
• Gonadorelin: Previously-approved gonadorelin products (Factrel, Lutrepulse) have been withdrawn from the US market and are not currently commercially available. Not FDA-approved for male sexual dysfunction. Compounding of gonadorelin under Section 503A depends on the bulk drug substance's classification under FDA's ongoing §503A bulks evaluation; this is a separate and evolving regulatory analysis from the essentially-a-copy question.
• Regulatory landscape: Peptide bulk drug substances are undergoing significant regulatory change in 2026. FDA actions effective February 2026 and April 22, 2026 have updated the status of multiple peptides. Consult a licensed prescriber for current availability.

How PT-141 Differs from PDE5 Inhibitors: A Mechanism Comparison

The distinction between PT-141 and conventional ED medications is mechanistic, not merely pharmacological. Understanding it matters for determining which patients may benefit from each approach.

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) act peripherally. Corbin, in a 2004 International Journal of Impotence Research review, explained PDE5-inhibitor cGMP action by blocking its enzymatic degradation, prolonging the vasodilatory response to sexual arousal. Carson, in a 2006 Canadian Journal of Urology review, characterized PDE5-inhibitor pharmacokinetic differences in terms of onset, duration, and selectivity. These compounds amplify an existing vascular signal; they require some degree of intact arousal and nitric oxide signaling to function.

PT-141 is studied as a central melanocortin receptor agonist. Molinoff and colleagues, in the foundational 2003 Annals of the New York Academy of Sciences paper introducing PT-141's CNS mechanism, documented PT-141 engages central melanocortin receptors rather than the peripheral nitric oxide pathway. Shadiack and colleagues, in a 2007 Current Topics in Medicinal Chemistry review, discussed the melanocortin system's role in desire and arousal. The mechanistic distinction from PDE5 inhibitors is why PT-141 has been studied in different research populations, including men with mild-to-moderate ED in early Phase II work; PT-141 is not FDA-approved for erectile dysfunction in men, and those Phase II signals were not sufficient to support a male-ED indication.

Wright, in a 2006 International Journal of Clinical Practice review, compared PDE5 inhibitors, with pharmacokinetic differences that are relevant when men do not respond adequately to one agent. A licensed provider can evaluate which FDA-approved ED treatment is appropriate based on an individual's clinical profile.

Considerations When Comparing Peptides for Erectile Dysfunction

Direct comparison between PT-141, kisspeptin, and gonadorelin is not methodologically sound. These compounds have been studied in different populations, using different endpoints, at different development stages. Inferring relative effectiveness from separate trials is unreliable.

The specific mechanism contributing to ED: Erectile dysfunction driven primarily by inadequate arousal signaling or desire deficit is mechanistically distinct from ED driven by low testosterone, which is distinct from ED driven by vascular insufficiency. A provider will assess which of these mechanisms predominates before any compound discussion is relevant.

Existing hormonal profile: Total testosterone and luteinizing hormone levels together characterize whether low testosterone is primary (testicular failure) or secondary (reduced HPG drive). This distinction determines whether an HPG-axis-targeting compound like kisspeptin or gonadorelin is mechanistically appropriate.

PDE5 inhibitor response history: Men who have had an adequate response to sildenafil or tadalafil have an intact vascular pathway. Men with an inadequate PDE5 inhibitor response should discuss alternative options with a licensed provider; peptides are not an established second-line therapy, and PT-141 is not FDA-approved for erectile dysfunction in men.

Comorbidities: Metabolic syndrome, diabetes, and cardiovascular disease are associated with vascular ED that may not respond to centrally acting peptides regardless of mechanism. Biomarker evaluation that includes HbA1c and inflammatory markers provides clinical context.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate full health history, current medications, and baseline lab values before recommending any compound.

Safety Considerations

Safety profiles differ substantially across this compound group. No blanket statement about peptide safety applies.

PT-141 (bremelanotide) carries documented adverse effects (from FDA-approved Vyleesi labeling, studied in premenopausal women with HSDD) including nausea (most common), flushing, headache, and transient blood pressure elevation. White and colleagues documented in a 2017 ambulatory monitoring study in the Journal of Hypertension that BP elevation is transient, typically resolving within 12 hours. Individuals taking nitrates or other vasodilators, or with uncontrolled hypertension or cardiovascular disease, should not use bremelanotide without provider evaluation. The adverse event profile of compounded bremelanotide used off-label for ED in men has not been characterized through adequate and well-controlled trials in that population. Any prescription peptide discussed in this article requires a licensed provider's evaluation.

Contraindications that apply broadly to peptide therapy in this context include:

• Uncontrolled cardiovascular disease or uncontrolled hypertension — particularly relevant for PT-141 given its transient BP effects
• Active or history of hormone-sensitive malignancy — HPG-axis-stimulating compounds carry theoretical concern; relevant for kisspeptin and gonadorelin
• Known hypersensitivity to any component of the specific formulation
• Concurrent use of vasodilatory medications without provider evaluation — potential additive effects on blood pressure
• Men with primary hypogonadism — HPG-axis-targeting compounds are not effective when the primary deficiency is testicular rather than hypothalamic-pituitary

For compound-specific side effect profiles, see the individual compound pages linked above.

What to Test Before Starting Peptides for Erectile Dysfunction

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes what is actually driving erectile dysfunction in your individual case. Without it, there is no objective way to determine whether a peptide's mechanism addresses your specific physiology — or whether the relevant contributing factor is something else entirely.

• Total testosterone: The primary hormonal screen for hypogonadism as an ED contributor. Total testosterone below the reference range warrants further evaluation before any peptide discussion.
• Free testosterone: The biologically active fraction; high SHBG can produce a normal total testosterone with low bioavailable testosterone. Free testosterone clarifies the active hormonal picture.
• LH and FSH: These upstream markers distinguish primary from secondary hypogonadism, which determines whether HPG-axis-targeting compounds are mechanistically appropriate. Luteinizing hormone and FSH establish the HPG axis picture.
• Estradiol: Excessive aromatization of testosterone to estradiol contributes to both low free testosterone and reduced libido. Estradiol testing provides the aromatization context.
• SHBG: Elevated sex hormone-binding globulin reduces free testosterone bioavailability; SHBG is essential for interpreting total testosterone.
• Prolactin: Hyperprolactinemia is a reversible cause of low testosterone and ED; elevated prolactin warrants evaluation for pituitary pathology before any peptide protocol.
• Fasting glucose and HbA1c: Metabolic dysregulation is a major driver of vascular and neurogenic ED. Fasting glucose and HbA1c establish metabolic baseline.
• hs-CRP: Systemic inflammation is associated with endothelial dysfunction and vascular ED. Baseline hs-CRP provides the inflammatory context.

Total testosterone, LH, FSH, estradiol, SHBG, and prolactin together establish the full hormonal picture. Glucose, HbA1c, and hs-CRP establish the metabolic and vascular context. Testing through a comprehensive hormonal baseline panel before any provider conversation about peptide therapy provides the data needed for a meaningful clinical evaluation rather than an empirical trial.

Evaluating ED with a Licensed Provider

FDA-approved treatments for erectile dysfunction in men include PDE5 inhibitors (sildenafil, tadalafil, vardenafil). These require a prescription from a licensed healthcare provider who evaluates eligibility via health history, symptom assessment, and laboratory work. A provider evaluation for ED typically involves baseline hormonal and metabolic bloodwork, a review of prior ED treatment history (including PDE5 inhibitor response), cardiovascular risk assessment, and a discussion of which contributing mechanisms are most relevant for the individual.

None of the peptides discussed in this article is FDA-approved for erectile dysfunction in men. PT-141 (bremelanotide) is FDA-approved as Vyleesi only for HSDD in premenopausal women; compounded bremelanotide used off-label for ED has not been evaluated or approved by the FDA. Kisspeptin is not available through 503A compounding pharmacies for therapeutic use. Gonadorelin is not FDA-approved for sexual dysfunction. Men with an inadequate response to PDE5 inhibitors should discuss alternative FDA-approved options with a licensed provider.

Self-directed use of any prescription or unapproved compound without a provider creates specific risks: contraindications related to blood pressure and cardiovascular status require clinical assessment; the absence of baseline labs means there is no way to determine whether the compound's mechanism addresses the actual contributing cause of the dysfunction. Products marketed outside licensed pharmacy channels lack pharmaceutical-grade manufacturing standards and operate outside FDA oversight.

Understanding Your Baseline

Erectile dysfunction is mechanistically heterogeneous. Whether the primary driver is hormonal, vascular, neurological, or some combination depends on individual biology — and the answer changes which compounds, if any, are appropriate to discuss. Baseline biomarker data transforms this from a guess into a clinical evaluation grounded in measurable physiology.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to an evaluation for PT-141, a hormonal assessment, a conventional PDE5 inhibitor, or a lifestyle-first approach, the starting point is the same: knowing where your biomarkers stand.

Important Safety Information

PT-141 (bremelanotide) is FDA-approved as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not FDA-approved for erectile dysfunction in men. Full prescribing information for the approved product is available in its FDA-approved labeling. Uses outside the approved indication, including use for erectile dysfunction in men, are off-label. Off-label prescribing is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA for this use. Compounded bremelanotide is not the FDA-approved product Vyleesi. Superpower members can connect with licensed providers through the Superpower platform; Superpower does not prescribe or dispense medications.

Warnings: Bremelanotide is associated with transient mean increases of approximately 1.9 mmHg systolic and 1.7 mmHg diastolic over 24 hours, with higher peak effects within the first several hours post-dose, as described in the FDA-approved Vyleesi prescribing information. Blood pressure returns to baseline within 12 hours in most individuals in the HSDD studies. Do not use if you have uncontrolled hypertension or known cardiovascular disease without clinical evaluation. Do not use with organic nitrates or other vasodilators without provider guidance. Not established as safe in pregnancy.

Common side effects reported in FDA-approved Vyleesi labeling (studied in premenopausal women with HSDD) include nausea (40%), flushing (20%), injection-site bruising (12%), and headache (11%). Hyperpigmentation of the face, gums, and breasts has been reported with chronic use. These figures are from the FDA-approved product labeling for the HSDD-in-women indication. The adverse event profile of compounded bremelanotide used off-label for ED in men has not been characterized through adequate and well-controlled trials in that population.

Kisspeptin is not FDA-approved for any indication. Kisspeptin is not on the FDA 503A bulks list, is not a component of an FDA-approved drug, and is not the subject of a USP/NF monograph; it is not available through 503A compounding pharmacies for therapeutic use in the United States. Research use is limited to academic research settings. Superpower does not facilitate access to kisspeptin.

Gonadorelin is not FDA-approved for sexual dysfunction. Previously-approved gonadorelin products (Factrel, Lutrepulse) have been withdrawn from the US market. Any use for erectile dysfunction is off-label. Safety and efficacy for this indication have not been established through adequate and well-controlled clinical trials. Superpower does not facilitate access to gonadorelin for ED.

Peptide bulk drug substances are undergoing significant regulatory change in 2026. FDA actions effective February 2026 and April 22, 2026 have updated the status of multiple peptides. Consult a licensed prescriber for current availability.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses multiple peptide compounds with different regulatory statuses. PT-141 (bremelanotide) is FDA-approved as Vyleesi only for HSDD in premenopausal women; it is not FDA-approved for erectile dysfunction in men, and any such use is off-label. Kisspeptin is not available through 503A compounding pharmacies for therapeutic use. Gonadorelin is not FDA-approved for sexual dysfunction. This educational content is editorially independent. Superpower does not prescribe or dispense medications.